Drawing for CLINTEC

USPTO serial 79100249

CLINTEC

Reviewed by CopyMark Law Group

Reg. 4162941Status 706Registered
Filing date
Status date
Registration date
Jun 26, 2012
Examiner
CARROLL, DORITT
Law office
GENERIC WEB UPDATE

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with CLINTEC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Arlene D. Hanks

Arlene D. Hanks Moore & Van Allen PLLC100 North Tryon StreetSuite 4700Charlotte, NC 28202-4003

Goods and services

ClassDescriptionStatusFirst use
035Business consultation in the field of clinical research [ and pharmaceutical commercialisation; ] compilation and systemization of information into computer databases; database management for others of a database comprised of data collected for clinical and biostatistics research purposes; personnel recruitment and placement in the field of clinical research; compilation and provision of statistical analysis reports; [ statistical consulting services for pharmaceutical, biotechnology and medical device industries for business purposes; ] creation and implementation of statistical analysis plans for business purposes; writing of business reports; business strategic planning [ ; market research, assessment, analysis and evaluation; business feasibility studies ]ACTIVE—
041[ Educational and ] training services in the field of clinical trials regulation and clinical research; [ Providing, arranging and conducting workshops, seminars, and educational conferences in the field of clinical trials regulation and clinical research; ] training in data capture and management; training [ and education ] in regulatory affairs; [ Providing, arranging and conducting training and educational classes, workshops, seminars, and education conferences in medical writing; providing, arranging and conducting training and educational classes, workshops, seminars, and education conferences training and education in quality control, auditing and inspection; writing of texts; ] training services, namely, training of clinical and scientific researchers to conduct clinical research and drug development studiesACTIVE—
042Scientific and technological services and research and design in the field of clinical trials and clinical research; industrial analysis and research services in the field of clinical trials and clinical research; clinical research services, namely, implementation of clinical studies and providing reports thereon; [ management of scientific research projects; conducting clinical research projects in the field of clinical trials and clinical research; ] conducting and monitoring clinical trials [ ; quality audit services, quality assurance consultancy, quality control testing in the field of quality control for others; technical inspection services, namely, inspection of clinical data, clinical procedure, clinical process, clinical database, and clinical reports for others; pharmaceutical product evaluation; design and conducting of technical feasibility studies; drug development services; quality management of drug development; preparation of reports in relation to clinical trials and clinical research, including preparation of reports on management of scientific research projects, clinical research projects, clinical trials, audits, pharmaceutical product evaluations, drug development and pharmaceutical product evaluations ]ACTIVE—
045[ Advisory and consultancy services relating to regulatory affairs in the field of clinical trials, clinical research and drug development; ] advisory and consultancy services relating to national and international regulation of clinical trials and drug developmentACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 17, 2024INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Feb 3, 2024INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Feb 2, 2024INPCINVALIDATION PROCESSED—
Jan 24, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
May 24, 2023NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
May 24, 202371AGREGISTERED-SEC.71 ACCEPTED—
May 22, 2023EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Dec 22, 2022PR71POST REGISTRATION ACTION MAILED - SEC.71—
Dec 22, 2022XXXXPOST REGISTRATION ACTION CORRECTION—
Dec 22, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 29, 2022ES71TEAS SECTION 71 RECEIVED—
Jun 26, 2021REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Mar 25, 2021RNWLINTERNATIONAL REGISTRATION RENEWED—
Jan 22, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jan 15, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 15, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 2, 2017NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Dec 2, 2017C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Dec 1, 2017APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 3, 2017ES75TEAS SECTION 71 & 15 RECEIVED—
Jun 26, 2017REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Sep 28, 2014ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 28, 2014REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 6, 2013ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 6, 2013REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 2, 2012GPNXNOTIFICATION PROCESSED BY IB—
Oct 15, 2012FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 26, 2012FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 26, 2012FIMPFINAL DISPOSITION PROCESSED—
Sep 26, 2012FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 26, 2012R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 17, 2012CORRCORRECTION FROM IB ENTERED - NO REVIEW REQUIRED—
May 11, 2012CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Apr 10, 2012NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 10, 2012PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 4, 2012OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 4, 2012OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 21, 2012NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 5, 2012PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 29, 2012ALIEASSIGNED TO LIE—
Feb 11, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 10, 2012TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 10, 2012CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 10, 2012TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 18, 2011ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 18, 2011REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 27, 2011RFNPREFUSAL PROCESSED BY IB—
Aug 11, 2011MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 10, 2011RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 10, 2011RFRRREFUSAL PROCESSED BY MPU—
Aug 10, 2011RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 9, 2011CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 8, 2011DOCKASSIGNED TO EXAMINER—
Aug 7, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 4, 2011REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance